Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer Agensys.

‘We believe AGS-16M8F, which is an ADC made to deliver the potent cytotoxic agent MMAF directly to tumor cells, has the potential to offer a new therapeutic option for this disease.’ Related StoriesStudy displays rare HER2 missense mutations do not spread breasts cancer on their ownCrucial change in one DNA base predisposes children to aggressive type of cancerViralytics enters into clinical trial collaboration agreement with MSDThe single-agent, Stage I, open-label, dose-escalation research will evaluate the basic safety and tolerability of AGS-16M8F in individuals with renal cancer and identify the maximum tolerated dose.The lower level of cognitive function at baseline in the mixed group with postoperative delirium, in comparison with the group without delirium, may have been related to a larger burden of preexisting disease that was not fully addressed in our multivariate versions. Postoperative cognitive decline in patients with delirium could be the continuation of a trajectory of decline that started before surgery.47 Since we didn’t perform multiple preoperative assessments over time and did not add a nonsurgical assessment group, our study cannot address this query.